MC3R: A Target for Drug Development and Cancer Research (G4159)
MC3R: A Target for Drug Development and Cancer Research
MC3R (Mesothelin Carboxyless) is a protein that is expressed in various body tissues and is known for its role in cell signaling and adhesion. Several studies have identified potential drug targets and biomarkers associated with MC3R, making it an attractive target for researchers and pharmaceutical companies.
MC3R is a transmembrane protein that is expressed in various body tissues, including the skin, heart, liver, and brain. It is a member of the transmembrane glycoprotein (TMP) family and is characterized by the presence of a N-terminal alpha helix, A central 尾-page and a C-terminal domain. MC3R plays a key role in intercellular signaling and cell adhesion.
The way MC3R interacts with its ligands is through ligand binding through glycoprotein receptor tyrosine kinase (EGFR) on the cell membrane. EGFR is a common EGFR tyrosine kinase family receptor that binds to the ligand binding site on MC3R. When EGFR binds to MC3R ligand, it can activate the phosphorylation of EGFR tyrosine kinase, leading to the phosphorylation of MC3R, which leads to changes in a series of intracellular signaling pathways.
MC3R is also related to cell adhesion and cell migration. Studies have shown that MC3R can promote cell adhesion and migration, thereby playing an important role in tumor growth and development. In addition, MC3R is also related to intercellular signaling and cell proliferation. Studies have shown that MC3R can promote cell proliferation, thereby increasing tumor size and growth rate.
MC3R is also related to tumor invasion and metastasis. Studies have shown that MC3R can promote tumor invasion and metastasis, thereby increasing the tumor's destruction of surrounding tissues and the risk of distant metastasis.
The expression level of MC3R can be used as a target for tumor treatment. Some studies have shown that MC3R expression levels are positively correlated with tumor invasion and metastasis. In addition, MC3R expression level can also be used as a biomarker to predict the survival rate of tumor patients. Studies have shown that tumor patients with lower MC3R expression levels have lower survival rates, while tumor patients with higher MC3R expression levels have higher survival rates.
MC3R can also serve as a drug target. Some studies have shown that MC3R can interact with some drugs, thereby affecting the efficacy and toxicity of the drugs. In addition, MC3R is also related to the occurrence and development of some diseases. For example, MC3R is associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Studies have shown that the expression level of MC3R is positively correlated with the occurrence and development of neurodegenerative diseases.
MC3R is of great significance in drug target research and breast cancer treatment. By studying the molecular mechanism and pharmacodynamics of MC3R, we can better understand the mode of action of MC3R and provide new ideas for the development of therapeutic drugs. In addition, studying MC3R can also provide new ideas for studying the pathogenesis of tumors.
Protein Name: Melanocortin 3 Receptor
Functions: Receptor for MSH (alpha, beta and gamma) and ACTH. This receptor is mediated by G proteins which activate adenylate cyclase. Required for expression of anticipatory patterns of activity and wakefulness during periods of limited nutrient availability and for the normal regulation of circadian clock activity in the brain
The "MC3R Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MC3R comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MC4R | MC5R | MCAM | MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24
